FDA widens GLP-1 import alert; adds orforglipron to the Green List
The September 21 revision of Import Alert 66-80 broadens detention-without-examination to more peptide product codes and names which foreign API makers have cleared FDA's bar.
Published October 3, 2026 · Twenty Residues editorial
What the record establishes
- Import Alert 66-80 ("Detention Without Physical Examination of GLP-1 Receptor Agonist Bulk Drug Substances") was republished September 21, 2026.
- FDA says that of 48 GLP-1 API sites it evaluated, 21% were noncompliant with manufacturing standards, and describes a pattern of firms registering as GLP-1 API makers, refusing records requests, then deregistering.
- The Green List names firms and drugs excluded from detention. Orforglipron API was added for three manufacturers in China and one in Ireland; an orforglipron drug-product intermediate was added for one Portugal-based manufacturer.
- Covered product codes include semaglutide, tirzepatide, liraglutide, exenatide, and dulaglutide, plus additional hormone and peptide codes.
What it does not establish
- The alert concerns bulk API entering the U.S. supply chain for compounding and manufacturing. It does not, by itself, say anything about the quality of any finished product sold to consumers.
- Being absent from the Green List is not a finding of noncompliance. It means FDA has not evaluated the firm against the criteria, or the firm has not applied.
- The alert is not a ban on GLP-1 imports. Listed firms continue to ship.
What would change this
A published list of the 21% noncompliant sites, or an FDA statement connecting a specific detained shipment to a named downstream seller, would turn this from supply-chain policy into a consumer-facing story.
The open question
If one in five inspected GLP-1 API sites fails FDA's standard, what does that imply about the API behind products that never pass through an inspected site at all?
We don't answer this one. Take it to wherever you argue about peptides, and send us the strongest case from either side.
Propose a question by emailor on the public record
Sources
- [1]Import Alert 66-80 (FDA, published 2026-09-21)
primaryFDA import alert
Related
FDA sends warning letters to five online peptide sellers in one day
Letters dated August 24, 2026 name NuScience Peptides, Royal Peptides, Peptide Partners, Peak Performance Peptides, and TXP Innovations. FDA says 'research use only' labels did not change its reading of intended use.
2 primary records · 1 secondary
FDA advisory panel recommends six peptides for the compounding list, over staff objections
At its July 23–24, 2026 meeting the Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon for the 503A Bulks List and against emideltide (DSIP). The vote changes nothing yet.
1 primary record · 2 secondary